Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

3.658 +0.028 (+0.77%)
Streaming Delayed Price Updated: 10:05 AM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Via ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESSWIRE
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Via ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Via ACCESS Newswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Via ACCESS Newswire
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Via ACCESSWIRE
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024
XBIO stock results show that Xenetic Biosciences met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.